NAEVR praises champions for $10 billion funding boon

Article

With the enactment of the American Recovery and Reinvestment Act of 2009 (HR 1) in Denver, the National Alliance for Eye and Vision Research praised Congress and biomedical research champions that facilitated the $10 billion in funding for the National Institutes of Health.

Key Points

Washington, DC-With the enactment of the American Recovery and Reinvestment Act of 2009 (HR 1) in Denver, the National Alliance for Eye and Vision Research (NAEVR) praised Congress and biomedical research champions that facilitated the $10 billion in funding for the National Institutes of Health (NIH).

James Jorkasky, executive director of NAEVR, said, "NAEVR was pleased to support the efforts of Senators Tom Harkin (D-IA), Arlen Specter (R-PA), Richard Durbin (D-IL), and Majority Leader Harry Reid (D-NV) in the Senate, and Speaker Nancy Pelosi (D-CA) and Appropriations Committee Chair David Obey (D-WI) in the House, to include $10 billion in funding for the NIH. We thank them for their commitment to biomedical research and its power to create and sustain jobs through this economic stimulus bill. We also owe a great deal to Maine's Republican Sens. Nancy Collins and Olympia Snowe, who joined with Sen. Specter in demonstrating independence and leadership in ensuring that this measure passed in the Senate."

Jorkasky pointed out that the funding will create 70,000 jobs in the near term and will have an economic impact in every state, as NIH funding trickles down by supporting research at academic institutions nationwide.

Recent Videos
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
Ali Tafreshi sits down with Optometry Times to discuss Topcon's "Healthcare from the Eye" initiative.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
© 2025 MJH Life Sciences

All rights reserved.